Brii Bio Unveils Promising Phase 2 Trial Results for HBV Treatment Strategies

Late-Breaking Findings from Brii Bio's Phase 2 Studies

Brii Biosciences Limited unveiled new data at the AASLD 2026 conference in Denver, Colorado, highlighting promising results from its Phase 2 studies on BRII-179, a treatment candidate for chronic Hepatitis B virus (HBV) infection. The studies, named ENRICH and ENHANCE, among others, reveal the potential of a novel priming and enrichment strategy using BRII-179, aimed at improving patient responses to HBV therapies.

Overview of the Research

The research reflects findings from five Phase 2 studies focused on BRII-179, including ENSURE, ENRICH, and ENHANCE. These trials have demonstrated BRII-179's effectiveness in stimulating immune responses specific to HBV, which is crucial for achieving higher rates of functional cures in patients suffering from this pervasive infection.

Initial results from the ENSURE study suggest that BRII-179 significantly enhances immune responses, particularly in patients with elevated baseline levels of HBV surface antigen (HBsAg). In fact, Cohort 4 of the ENSURE study reported that 41.9% of participants lost HBsAg at the end of treatment, with 32.4% maintaining this loss for 24 weeks post-treatment.

Key Findings from ENRICH and ENHANCE Studies

The ENRICH study built on previous data, confirming BRII-179's potential as a priming agent. Participants received BRII-179, with 41.9% achieving HBsAg loss at the end of treatment, and 32.4% sustaining this loss during follow-up.

The ENHANCE study explored combining BRII-179 with two other therapies: elebsiran and pegylated interferon alpha (PEG-IFNα). Notably, participants receiving this triple combination demonstrated significantly higher HBsAg loss rates at the end of treatment (25.5%) compared to those receiving only PEG-IFNα (10.2%). Remarkably, among those with higher baseline HBsAg, the combination therapy maintained efficacy with a noted HBsAg loss rate of 24.2% at the end of treatment.

A fascinating aspect of these studies was the priming effect of BRII-179 seen in patients who developed anti-HBs responses, contributing to even better outcomes. The results consistently indicate that early intervention with BRII-179 can catalyze improved responses to subsequent therapies.

Safety and Tolerability

Throughout the studies, the safety profiles of the treatment regimens were generally favorable, with most reported adverse events aligning with those typically observed with PEG-IFNα treatment. This adds an encouraging layer to the prospects of implementing BRII-179 in broader HBV treatment paradigms.

Dr. David Margolis, Chief Medical Officer of Brii Bio, emphasized the significance of these findings, suggesting the data provides a robust scientific basis for the ongoing exploration of BRII-179-based strategies, particularly among patients with high HBsAg levels where curing the infection remains exceptionally challenging.

The Future of BRII-179 in HBV Treatment

Given the substantial impact of chronic HBV infection globally—affecting over 254 million people worldwide and resulting in approximately 820,000 deaths annually—it is imperative to develop effective treatments. BRII-179, with its innovative approach to enhancing HBV-specific immunity, could revolutionize therapeutic strategies against this stubborn disease.

The ongoing exploration of BRII-179 highlights its potential role in advancing treatment options for patients with chronic HBV, particularly in challenging cohorts. As more data emerges, there is optimism that these findings will pave the way for breakthroughs in achieving functional cures and improving overall patient outcomes in HBV treatment.